Baxalta, the soon-to-spin-out pharma arm of Baxter, has expanded its relationship with Israel's Kamada, agreeing to co-fund a trial testing whether the company's top prospect can prevent lung transplant rejections.
Immuno-oncology innovator Kite Pharma is joining gene therapy luminary bluebird bio to craft new treatments for HPV-related cancers, combining two high-profile technologies in hopes of developing targeted therapies.
Patrick Soon-Shiong thinks he can beat CAR-Ts in the clinic. And after quietly taking control of a small biotech named Conkwest, the biotech billionaire is now floating a $172.5 million IPO in a sizzling hot market to raise new funds for the midstage program that lies ahead.
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including buyout rumors surrounding GlaxoSmithKline, the new face of Allergan and a biotech IPO that's turning heads around the industry.
Amgen says that its experimental migraine drug boosted its response rate among patients over a full year of therapy, a little bit of an edge that could help it compete against a group of rivals now hustling ahead with pivotal studies.
Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.
Bayer is gearing up to spend more than ever before on R&D this year, CEO Marijn Dekkers said, investing in innovation with hopes of pushing some promising therapies onto the market.
Biotech startup engine PureTech pulled off a $171 million IPO on the London Stock Exchange, crossing the Atlantic to raise cash for its hybrid approach to venture investing.
Tekmira's in-development treatment for Ebola virus failed to move the needle in a midstage trial, leading the drugmaker to halt the study and sending its share value downward.
Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.
Austrian drug developer Nabriva Therapeutics is plotting to make its way to Wall Street in a $92 million IPO, raising cash to support its pipeline of treatments for infectious diseases.
FierceBiotech Radio is back with a two-part special from the BIO conference in Philadelphia.
At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.
In this week's EuroBiotech Report, Neil Woodford's fund got deeper into Circassia, pulled out of Sanofi and criticized GlaxoSmithKline for performing "poorly operationally." Servier scooped up regional rights to Taiho Pharmaceutical's refractory metastatic colorectal cancer drug in a $130 million (€115 million) deal. And more.
A phalanx of French biotechs rolled into New York this week for a meeting with life science investors. Among the 20 biotechs at the flesh-pressing festival were some laying the groundwork for IPOs on Nasdaq, including Eli Lilly-partnered diabetes player Adocia.
A Phase III victory for Synergy Pharmaceuticals' constipation drug has made the company an attractive takeout target, analysts say, with the acquisitive Valeant Pharmaceuticals a potential suitor.
Celyad and Chiasma have joined the growing list of European biotechs to barrel into Wall Street in search of dollars. The companies are aiming to raise a total of around $185 million (€164 million), a sum that will go toward a mix of late-phase trials and CAR-T R&D.
Boulder, CO-based Nivalis Therapeutics rode the hot market for biotech IPOs to a $77 million windfall, banking on a very early-stage cystic fibrosis effort that's looking to ride on the coattails of a new combo therapy from Vertex.
Fresh off of changing its name and posting some positive clinical results, Aimmune Therapeutics has picked up the FDA's coveted breakthrough therapy designation for its peanut allergy treatment, promising a speedy regulatory process for the company's lead drug.